Journal
Kidney International Reports
Publication Date
12-5-2020
Volume
6
Issue
3
First Page
624
Last Page
635
Document Type
Open Access Publication
DOI
10.1016/j.ekir.2020.11.034
Rights and Permissions
Coyne DW, Roger SD, Shin SK, Kim SG, Cadena AA, Moustafa MA, Chan TM, Besarab A, Chou W, Bradley C, Eyassu M, Leong R, Lee TT, Saikali KG, Szczech L, Yu KP. Roxadustat for CKD-related Anemia in Non-dialysis Patients. Kidney Int Rep. 2020 Dec 5;6(3):624-635. doi: 10.1016/j.ekir.2020.11.034 Copyright 2020 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY- NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Coyne, Daniel W and et al., "Roxadustat for CKD-related anemia in non-dialysis patients." Kidney International Reports. 6, 3. 624 - 635. (2020).
https://digitalcommons.wustl.edu/oa_4/621
Figure S1. Subgroup analysis of the primary US efficacy endpoint (ITT). Figure S2. Subgroup analysis of the primary EU efficacy endpoint (FAS). Table S1. Inclusion and exclusion criteria. Table S2. Roxadustat dose adjustment algorithm. Table S3. Fixed sequence for testing secondary efficacy endpoints. Table S4. Change from baseline to weeks 12 to 28 in LDL cholesterol by treatment and statin use (FAS). Table S5. Mean change from baseline for hepcidin and iron-related parameters at week 44 (FAS). Table S6. Summary of TEAEs∗ occurring in ≥5% of patients in either treatment group (W52) (SAF). Table S7. Summary of TESAEs∗ occurring in ≥1% of patients in either treatment group (W52) (SAF).
